luzindole has been researched along with s20098 in 10 studies
| Studies (luzindole) | Trials (luzindole) | Recent Studies (post-2010) (luzindole) | Studies (s20098) | Trials (s20098) | Recent Studies (post-2010) (s20098) |
|---|---|---|---|---|---|
| 265 | 1 | 119 | 624 | 87 | 422 |
| Protein | Taxonomy | luzindole (IC50) | s20098 (IC50) |
|---|---|---|---|
| Melatonin receptor type 1A | Homo sapiens (human) | 0.0001 | |
| Melatonin receptor type 1B | Homo sapiens (human) | 0.0001 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amossé, C; Audinot, V; Bonnaud, A; Boutin, JA; Delagrange, P; Dromaint, S; Galizzi, JP; Guillaumet, G; Lahaye-Brasseur, C; Le Gall, A; Lefoulon, F; Lesieur, D; Mailliet, F; Malpaux, B; Nagel, N; Renard, P; Rodriguez, M | 1 |
| Alonso-Gil, S; Caignard, DH; de la Fuente Revenga, M; Fernández-Sáez, N; Herrera-Arozamena, C; Morales-García, JA; Pérez-Castillo, A; Rivara, S; Rodríguez-Franco, MI | 1 |
| Bucher, B; Gauer, F; Masson-Pévet, M; Pévet, P | 1 |
| Flanders, S; Lew, MJ | 1 |
| Barrett, P; Conway, S; Delagrange, P; Drew, JE; Morgan, PJ; Mowat, ES | 1 |
| Gressens, P; Husson, I; Mocaer, E; Sarkozy, G; Schwendimann, L; Spedding, M; Vamecq, J | 1 |
| Chel'naia, NA; Iasnetsov, VV; Ivanov, IuV; Karsanova, SK; Motin, VG | 1 |
| Agarwal, NB; Azim, MS; Vohora, D | 1 |
| Yao, K; Zhao, YF; Zu, HB | 1 |
| Qi, ZX; Wei, ZX; Zhou, N | 1 |
10 other study(ies) available for luzindole and s20098
| Article | Year |
|---|---|
New selective ligands of human cloned melatonin MT1 and MT2 receptors.
Topics: Animals; Cell Line; CHO Cells; Cloning, Molecular; Cricetinae; Dose-Response Relationship, Drug; Humans; Ligands; Melatonin; Protein Binding; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2 | 2003 |
Novel N-Acetyl Bioisosteres of Melatonin: Melatonergic Receptor Pharmacology, Physicochemical Studies, and Phenotypic Assessment of Their Neurogenic Potential.
Topics: Animals; Cells, Cultured; CHO Cells; Cricetulus; Humans; Male; Melatonin; Models, Molecular; Neural Stem Cells; Neurogenesis; Oxadiazoles; Rats; Rats, Wistar; Receptors, Melatonin; Thiadiazoles | 2015 |
Vasoconstrictor effects of various melatonin analogs on the rat tail artery in the presence of phenylephrine.
Topics: Acetamides; Animals; Dose-Response Relationship, Drug; Drug Interactions; Endothelium; Male; Melatonin; Muscle, Smooth; Nerve Endings; Norepinephrine; Perfusion; Phenylephrine; Rats; Rats, Wistar; Receptors, Cell Surface; Receptors, Cytoplasmic and Nuclear; Receptors, Melatonin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sympathetic Nervous System; Tail; Tryptamines; Vasoconstriction | 1999 |
Mechanisms of melatonin-induced vasoconstriction in the rat tail artery: a paradigm of weak vasoconstriction.
Topics: Acetamides; Animals; Anticonvulsants; Arteries; Calcium Channel Blockers; Charybdotoxin; Colforsin; Dose-Response Relationship, Drug; Hypnotics and Sedatives; In Vitro Techniques; Indoles; Male; Melatonin; Nifedipine; Nitroprusside; Potassium Channels; Rats; Rats, Sprague-Dawley; Tail; Tryptamines; Vasoconstriction; Vasoconstrictor Agents; Vasodilator Agents; Vasopressins | 1999 |
Serine residues 110 and 114 are required for agonist binding but not antagonist binding to the melatonin MT(1) receptor.
Topics: Acetamides; Amides; Amino Acid Substitution; Animals; Binding Sites; Binding, Competitive; COS Cells; Cyclic AMP; Dose-Response Relationship, Drug; Heterotrimeric GTP-Binding Proteins; Humans; Indoles; Melatonin; Mutagenesis, Site-Directed; Naphthalenes; Protein Binding; Radioligand Assay; Receptors, Cell Surface; Receptors, Cytoplasmic and Nuclear; Receptors, Melatonin; Recombinant Fusion Proteins; Serine; Structure-Activity Relationship; Transfection; Tryptamines | 2001 |
Agomelatine, a melatonin receptor agonist with 5-HT(2C) receptor antagonist properties, protects the developing murine white matter against excitotoxicity.
Topics: Acetamides; Animals; Brain; Brain Diseases; Excitatory Amino Acid Agonists; Ibotenic Acid; Melatonin; Mice; Neuroprotective Agents; Receptor, Serotonin, 5-HT2C; Receptors, Melatonin; Serotonin Antagonists; Tryptamines | 2008 |
[Investigation into the vestibular protective properties of melatoninergic agents].
Topics: Acetamides; Animals; Animals, Newborn; Animals, Outbred Strains; Bicuculline; Central Nervous System Depressants; Excitatory Postsynaptic Potentials; GABA-A Receptor Antagonists; Male; Medulla Oblongata; Melatonin; Neurons; Patch-Clamp Techniques; Rats; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Tryptamines; Vestibule, Labyrinth | 2014 |
Effects of agomelatine on pentylenetetrazole-induced kindling, kindling-associated oxidative stress, and behavioral despair in mice and modulation of its actions by luzindole and 1-(m-chlorophenyl) piperazine.
Topics: Acetamides; Animals; Anticonvulsants; Antioxidants; Depression; Drug Therapy, Combination; Epilepsy; Hippocampus; Hypnotics and Sedatives; Kindling, Neurologic; Male; Mice; Oxidative Stress; Pentylenetetrazole; Seizures; Treatment Outcome; Tryptamines | 2017 |
Melatonin receptor stimulation by agomelatine prevents Aβ-induced tau phosphorylation and oxidative damage in PC12 cells.
Topics: Acetamides; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antidepressive Agents; Cell Survival; Malondialdehyde; Oxidative Stress; PC12 Cells; Peptide Fragments; Phosphorylation; Rats; Receptors, Melatonin; tau Proteins; Tryptamines | 2019 |
Inhibition of autophagy triggers melatonin-induced apoptosis in glioblastoma cells.
Topics: Acetamides; Antineoplastic Agents; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Glioblastoma; Humans; Macrolides; Melatonin; Receptors, Melatonin; Tryptamines | 2019 |